TLDR JAK inhibitors can help treat alopecia areata but have risks and high costs.
The document explores novel management options for alopecia areata (AA), emphasizing the role of JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—in treatment. These inhibitors have shown efficacy in reducing scalp hair loss in clinical trials involving thousands of patients, with significant improvements in SALT scores. However, they also pose risks of serious adverse events, requiring careful risk-benefit assessments. The document underscores challenges such as high treatment costs, insurance issues, and lack of disease awareness, which exacerbate the psychosocial impact of AA. It calls for managed care professionals to improve access to therapies and provide psychosocial support to enhance patient outcomes.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
October 2025 in “Journal of Advanced Trends in Medical Research” Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
